ADAM metallopeptidase domain 21 pseudogene 1Genealiases: []
Q-omics provides the consensus-scored ADAM21P1 profile across patient tissues and cancer cell-line models. ADAM21P1 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ADAM21P1 is differentially expressed in 10, with the highest sampling consensus in HNSC. Additionally, ADAM21P1 RNA expression shows 11,119 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, HNSC, and THYM as cancer lineages where ADAM21P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ADAM21P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ADAM21P1 survival associations across molecular data types. ADAM21P1 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ADAM21P1 RNA expression–survival associations across cancer types. High ADAM21P1 expression shows unfavorable associations in MESO, DLBC, READ, TGCT and SKCM, but favorable associations in UCS. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ADAM21P1 RNA expression.
This table summarizes ADAM21P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for ADAM21P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ADAM21P1 shows lower tumor expression in KICH and KIRC and higher tumor expression in HNSC, LIHC, BRCA and STAD. The HNSC box plot shows higher ADAM21P1 RNA expression in tumor versus normal tissue (log2 FC = +0.057, t-test p = .004).
This table shows molecular features associated with ADAM21P1 in patient tissues and cancer cell lines. In patient samples, ADAM21P1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
